TURKU, Finland, Oct 02, 2023–(Business WIRE)–Bonalive Biomaterials has appointed Jort Kooistra as vice president, Commercial Functions productive 2 October 2023. Jort Kooistra will bring his varied track record in business advancement, commercialization, and revenue, merged with his sturdy basis in health care instruction to Bonalive.
“We are excited to announce that this sort of an professional intercontinental wellbeing tech govt as Jort Kooistra is signing up for our team. He joins Bonalive, in this coming stage of progress, as we choose our commercialization to the upcoming stage with an increased concentration on combating the escalating obstacle of antimicrobial resistance, AMR”, Heidi Rantala, CEO of Bonalive.
Jort Koistra’s working experience in regenerative medicine is considerable, acquiring worked in lots of worldwide providers such as Depuy, Johnson & Johnson, RTI Surgical, Bioventus, and Bonesupport. He delivers to Bonalive his knowledge for advancing far more sustainable methods within just the health care sector. Jort Kooistra has an EMBA diploma from Nyenrode Enterprise University, and BSc degree in Bodily therapy from Hogeschool Utrecht.
“I am amazed with the understanding and the amount of international believed leadership within Bonalive that are dedicated to S53P4 bioactive glass. Bonalive is a company of the future – combating the frontline of the rising problem of antimicrobial resistance. I glance ahead to contributing to this future period of development to carry Bonalive’s Smart Therapeutic expertise to an raising quantity of surgeons and their patients all over the world”, Jort Kooistra, vice president, industrial functions, Bonalive Biomaterials.
About Bonalive Biomaterials
Bonalive is a sensible biomaterials company, combating the globally increasing challenge of antimicrobial resistance by reworking healthcare at the intersection of biology and technological innovation. Bonalive supplies sufferers and surgeons with properly-verified and risk-free bone regenerative products in orthopedics, trauma, backbone, septic bone surgical treatment, diabetic foot osteomyelitis, benign bone tumor, and mastoid surgery. With more than 20 years of clinical background and 1 of the most evidence-centered systems in the business, we are re-imagining a globe the place bacterial infections can be treated without having antibiotics. It really is time to recover smarter. #SmartHealing
For even further information and facts, be sure to go to: www.bonalive.com.
Watch supply version on businesswire.com: https://www.businesswire.com/news/home/20231001172792/en/
CEO, Bonalive Biomaterials